Gene
ATM
ATM is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (68), Actionable biomarkers (13), and 8 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
3 more sections with rows · 1 section measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ATM. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 34 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 13 of 8,738 | 0.15% | not measured | |
| 2025 | 17 of 8,875 | 0.19% | not measured | |
| 2024 | 16 of 8,597 | 0.19% | not measured | |
| 2023 | 21 of 8,275 | 0.25% | 71 of 11,460 | 0.62% |
| 2022 | 25 of 8,285 | 0.30% | 104 of 13,598 | 0.76% |
| 2021 | 31 of 8,692 | 0.36% | 109 of 15,045 | 0.72% |
| 2020 | 21 of 7,640 | 0.27% | 86 of 14,459 | 0.59% |
| 2019 | 21 of 7,300 | 0.29% | 94 of 12,159 | 0.77% |
| 2018 | 23 of 6,927 | 0.33% | 87 of 11,854 | 0.73% |
| 2017 | 13 of 6,558 | 0.20% | 57 of 11,595 | 0.49% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| FoundationOne Liquid CDx | ATM | Foundation Medicine, Inc. | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | 2020-11-06 |
Assay-provider ledger (68)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent Technologies | Reagent supplier | Clinical validationAnalytical validation | 4 | March 01, 2026 |
| GE HealthCare | Context dependent | No clinical or analytical validation recorded for this pair | 1 | March 01, 2026 |
| Illumina | Unclassified | Clinical validationAnalytical validation | 10 | March 01, 2026 +1 undated |
| Macrogen | Unclassified | No clinical or analytical validation recorded for this pair | 1 | March 01, 2026 |
| Miltenyi Biotec | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | March 01, 2026 |
Showing 5 of 68 assay-provider companies.
Actionable biomarkers (13)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ATM oncogenic mutation | Atr Inhibitors | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| ATM deletion | Atr Inhibitors | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| ATM oncogenic mutation | OLAPARIB | response-associated | gastric carcinoma | Cancer Genome Interpreter |
| ATM deletion | Parp Inhibitors | response-associated | gastric carcinoma | Cancer Genome Interpreter |
| ATM oncogenic mutation | Parp Inhibitors | response-associated | gastric carcinoma | Cancer Genome Interpreter |
Showing 5 of 13 actionable-biomarker assertions.
Trial mentions (252)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00214227 | Trial biospecimen (AACT) |
| NCT02511223 | Trial eligibility (AACT) |
| NCT06078670 | Trial eligibility (AACT) |
| NCT06177171 | Trial eligibility (AACT) |
| NCT05761470 | Trial eligibility (AACT) |
Showing 5 of 252 trial mentions.
Target-disease associations (1,152)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| 3-phosphoinositide-dependent protein kinase 1 measurement | measurement | GWAS credible sets |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
| 46,XY disorder of sex development due to isolated 17,20 lyase deficiency | cancer or benign tumor | Mouse knockout (IMPC) |
| 46,XY gonadal dysgenesis - motor and sensory neuropathy | cancer or benign tumor | Mouse knockout (IMPC) |
Showing 5 of 1,152 associations.
Vendor sourcing (965)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple path... | View ClinVar record SCV002012008.1 |
| A-T Children's Project | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * A-T patients who visit our outpatient clinic. * Genetically confirmed diagnosis of A-T by the identification of pathogenic mutations of the ATM gene. * ... | View trial NCT03962114 |
| A-T Children's Project | Trial collaborator | Mentioned in trial textTrial free-text mention | ATM | View trial NCT03962114 |
| AC Camargo Hospital | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The ATM c.7273G>A (p.Gly2425Ser) missense variant is located within the final 34 bp of exon 49 and results in the substitution of a nonpolar glycine residue ... | View ClinVar record SCV006555115.1 |
| AHS Cancer Control Alberta | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Age ≥ 18 years * Life expectancy of ≥ 3 months * Histologically or cytologically confirmed locally recurrent or metastatic breast cancer that is Estroge... | View trial NCT04149444 |
Showing 5 of 965 sourcing records.
Trial-cited literature (996)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia. | Blood | 2026 | 4 |
| Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. | JCO precision oncology | 2026 | 0 |
| Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. | Blood neoplasia | 2026 | 0 |
| Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 55 |
| Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. | Nature medicine | 2025 | 37 |
Showing 5 of 996 papers.
Protein variant mentions (1,042)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1059V | 1 | 2015 | PMID 25741868 |
| p.A1079T | 1 | 2015 | PMID 25741868 |
| p.A108T | 1 | 2015 | PMID 25741868 |
| p.A1110T | 1 | 2015 | PMID 25741868 |
| p.A112T | 2 | 2015 to 2016 | PMID 27443514, PMID 25741868 |
Showing 5 of 1,042 variants.
Human sample screening reference (13)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.D2721N | MMRF-COMMPASS | Plasma Cell Tumors; Hematopoietic and reticuloendothelial systems | 1 | 961 | 0.10% | 0.02% to 0.59% |
| p.D2721N | TCGA-COAD | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Complex Epithelial Neoplasms; Rectosigmoid junction; Colon | 1 | 461 | 0.22% | 0.04% to 1.22% |
| p.K2413Q | TCGA-LUAD | Cystic, Mucinous and Serous Neoplasms; Ductal and Lobular Neoplasms; Acinar Cell Neoplasms; Adenomas and Adenocarcinomas; Bronchus and lung | 1 | 573 | 0.17% | 0.03% to 0.98% |
| p.R250* | CPTAC-3 | Not Applicable; Transitional Cell Papillomas and Carcinomas; Ductal and Lobular Neoplasms; Adenomas and Adenocarcinomas; Gliomas; Epithelial Neoplasms, NOS; Complex Epithelial Neoplasms; Complex Mixed and Stromal Neoplasms; Lipomatous Neoplasms; Squamous Cell Neoplasms; Myeloid Leukemias; Nevi and Melanomas; Stomach; Other and ill-defined sites in lip, oral cavity and pharynx; Unknown; Colon; Other and unspecified urinary organs; Floor of mouth; Other and unspecified parts of mouth; Gum; Bronchus and lung; Oropharynx; Other and unspecified parts of tongue; Base of tongue; Breast; Other and ill-defined sites; Larynx; Lip; Uterus, NOS; Hematopoietic and reticuloendothelial systems; Kidney; Brain; Skin; Pancreas; Tonsil | 1 | 1,815 | 0.06% | 0.01% to 0.31% |
| p.R250* | TCGA-BLCA | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Squamous Cell Neoplasms; Transitional Cell Papillomas and Carcinomas; Bladder | 1 | 412 | 0.24% | 0.04% to 1.36% |
Showing 5 of 13 cohort observations.
Literature-extracted relations (204)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Inotuzumab Ozogamicin | Chemical | negative_correlate |
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. | 2024 |
| CARBOPLATIN | Chemical | associate |
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial. | 2024 |
| IPILIMUMAB | Chemical | associate |
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. | 2023 |
| NIVOLUMAB | Chemical | associate |
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. | 2023 |
| Trabectedin | Chemical | associate |
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination. | 2022 |
Showing 5 of 204 relation assertions.
Organizations publishing (765)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 64 | 1998 to 2024 |
| Memorial Sloan Kettering Cancer Center | Hospital | 60 | 1999 to 2026 |
| The University of Texas System | Academic | 55 | 2008 to 2026 |
| Dana-Farber Cancer Institute | Other | 43 | 2009 to 2025 |
| Harvard Medical School | Academic | 37 | 2005 to 2025 |
Showing 5 of 765 organizations.
Where ATM appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
934 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects.